Prism Pharmaceuticals was founded in 2004 by Essex Woodland Health Ventures. The company is led by Dr. Warren Cooper and a management team with diverse and extensive experience in the development, launch, and commercial success of cardiovascular products.

Executive Officers and Directors

Warren D. Cooper, MB, BS, BSc, MFPM
President and Chief Executive Officer
Warren is a UK-trained physician with over 25 years in the global pharmaceutical industry. With a background in cardiology and cardiac surgery, he spent 12 years with Merck, initially as a UK clinical research physician, then as head of European and Worldwide Clinical Research Operations for Merck Research Laboratories across all therapeutic areas. Moving to AstraMerck (now AstraZeneca PLC), he led that company’s cardiovascular business division, a role with full business lifecycle leadership from in-licensing through development to P&L responsibility for sales and marketing. Warren then founded a healthcare consulting practice, Coalescence Inc., which he led for five years prior to joining Prism. Warren is a member of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom and is a member of the American Association of Pharmaceutical Physicians and the American and International Societies of Hypertension.

Kathleen DeLawrence
Vice President, Strategic and Commercial Operations and
Chief Operating Officer
Kathleen brings over 15 years of pharmaceutical industry experience that includes general management, product launch management, marketing and sales operations management, and merger integration. Most recently she was VP and General Manager for a medical communications agency where she assumed operational responsibility for this business when it was privately held and was directly responsible for leading it through two consecutive acquisitions by publicly-held firms. Kathleen spent the prior 8 years at AstraMerck (now AstraZeneca PLC) in Commercial Operations, acquiring increased responsibility in roles including product launch management, commercial operations director, and leading merger integration for marketing and sales during the Astra and Zeneca merger. Kathleen has enjoyed a successful career over 20 years working for several of the top Fortune 500 companies: CardinalHealth, AstraZeneca, Price Waterhouse, and General Electric. Her cross-industry experiences include a range of management consulting and corporate assignments where her skills were applied in information systems integration, business process reengineering, organizational design, and change management.

Stanley J. Musial, CPA, MBA
Chief Financial Officer
Stan was most recently a Partner with Carrow, Doyle and Associates. Prior to joining the firm he held the position of VP, Finance and CFO for Strategic Diagnostics, Inc., a publicly-held (SDIX) agricultural biotechnology company. Prior to joining SDIX, Stan was Senior VP, Finance and CFO for Continuum Healthcare, Inc., a privately-held, venture capital-backed specialty healthcare company. He previously held senior financial management positions with Orthovita, Inc., a publicly-held (VITA) orthopedic biotechnology company; Occupational Health Resources, Inc., a venture capital- backed physician practice management company; Surgical Laser Technologies, Inc., a publicly-held (SLTI) laser surgery company; and Environmental Control Group, Inc., a publicly-held (ECGI) environmental services company. He began his career with KPMG LLP. Stan holds an MBA in finance from Temple University and a B.S. degree in accounting from Pennsylvania State University and is a Certified Public Accountant.

John Nicastro
Vice President, Marketing
John Nicastro joined Prism as VP, Marketing with 20 years of product marketing experience in the animal health and pharmaceutical industries. John launched his career on the agency side of the business, developing advertising and marketing campaigns in both animal health and traditional pharmaceuticals. As a marketing director, his client portfolio included key companies such as Merck, AstraMerck, Pfizer, and Novartis. He transitioned this experience into pharmaceutical marketing when he joined AstraMerck. During his tenure at AstraMerck (now AstraZeneca PLC), John rose through the product marketing ranks, collecting valuable experience in product promotion, marketing, brand development and management, product launches, and direct selling. The pinnacle of this experience was the four years he spent as a brand director focused on the launch of Crestor. Most recently, John was Director of Business Development for the medical education division of CardinalHealth.

Daniel J. Cushing, PhD, FCP
Vice President, Drug Development and Regulatory Affairs
Dan has over 15 years of pharmaceutical industry experience, including discovery research, drug development, medical affairs, and regulatory affairs. Over his career, he has led the strategy, preparation, and management of several successful INDs and NDAs and launched multiple cardiovascular brands that still enjoy success in the market. Prior to joining Prism he worked at Pfizer, Merck, and AstraMerck (now AstraZeneca PLC), where he held senior positions in medical and regulatory affairs. Most recently, Dan leveraged his pharmaceutical experience and built a successful consulting firm (Scientific Commercialization LLC) and continued to serve the pharmaceutical and medical device industries. Dan holds a Ph.D. in pharmacology and is a Fellow of the American College of Clinical Pharmacology.